Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Liver Cancer
المؤلفون الرئيسيون:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Karger Publishers 2023-05-01
الموضوعات:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
الوصول للمادة أونلاين:	https://beta.karger.com/Article/FullText/531182

مواد مشابهة

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
حسب: Hannah Yang, وآخرون
منشور في: (2023-04-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
حسب: Young Eun Chon, وآخرون
منشور في: (2023-02-01)

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
حسب: Young Eun Chon, وآخرون
منشور في: (2024-07-01)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
حسب: Yong Tae Kim, وآخرون
منشور في: (2023-03-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
حسب: Tae Hyun Kim, وآخرون
منشور في: (2023-09-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
حسب: Jaekyung Cheon, وآخرون
منشور في: (2025-01-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
حسب: Tetsu Tomonari, وآخرون
منشور في: (2023-02-01)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
حسب: Sri Harsha Tella, وآخرون
منشور في: (2022-06-01)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
حسب: Sun Hyun Bae, وآخرون
منشور في: (2023-09-01)

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
حسب: F. Rossari, وآخرون
منشور في: (2025-06-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
حسب: Tomoyuki Satake, وآخرون
منشور في: (2023-07-01)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
حسب: Kazuhiro Nouso, وآخرون
منشور في: (2023-09-01)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
حسب: Hyung Jun Kim, وآخرون
منشور في: (2023-03-01)

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
حسب: Sun Young Yim, وآخرون
منشور في: (2024-10-01)

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
حسب: Young Eun Chon, وآخرون
منشور في: (2024-10-01)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
حسب: Yuri Cho, وآخرون
منشور في: (2023-03-01)

Brain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
حسب: Bangju Kim, وآخرون
منشور في: (2025-06-01)

Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
حسب: Etsuko Moriyama, وآخرون
منشور في: (2024-09-01)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
حسب: Takahiro Niimura, وآخرون
منشور في: (2023-08-01)

Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
حسب: Choong-kun Lee, وآخرون
منشور في: (2024-08-01)

Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma
حسب: Shaobo Zhang, وآخرون
منشور في: (2025-05-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
حسب: Ryosuke Tsunemitsu, وآخرون
منشور في: (2023-06-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
حسب: Masatoshi Kudo
منشور في: (2021-02-01)

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study
حسب: Merin Babu, وآخرون
منشور في: (2025-07-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
حسب: Zili Hu, وآخرون
منشور في: (2024-11-01)

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
حسب: Shen X, وآخرون
منشور في: (2024-10-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
حسب: Yasuhito Mitsuyama, MD, وآخرون
منشور في: (2023-09-01)

A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma
حسب: Hiroki Kawanaka, وآخرون
منشور في: (2024-01-01)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
حسب: Zanuso V, وآخرون
منشور في: (2023-10-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
حسب: Parissa Tabrizian, وآخرون
منشور في: (2025-02-01)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
حسب: Yasuto Takeuchi, وآخرون
منشور في: (2023-09-01)

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
حسب: Jaekyung Cheon, وآخرون
منشور في: (2023-01-01)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
حسب: Shigeo Shimose, وآخرون
منشور في: (2023-06-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
حسب: Sae Yumita, وآخرون
منشور في: (2023-03-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
حسب: Hironori Ochi, وآخرون
منشور في: (2025-01-01)

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
حسب: Masatoshi Kudo, وآخرون
منشور في: (2023-11-01)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
حسب: Han Seul Kim, وآخرون
منشور في: (2023-08-01)

Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
حسب: Ji Yeon Lee, وآخرون
منشور في: (2024-12-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
حسب: Hongyu Gong, وآخرون
منشور في: (2023-03-01)

Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis
حسب: Linhan Jiang, وآخرون
منشور في: (2021-10-01)